Drug Trial News

RSS

Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

Experts from Children's Hospital Colorado (Children's Colorado) co-led a team of researchers in studying new approaches to reducing fall asthma exacerbations in pediatric patients.

18 Jan 2016

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina.

18 Jan 2016

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH's National Institute of Allergy and Infectious Diseases (NIAID).

17 Jan 2016

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).

13 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

A clinical trial using cholesterol-lowering treatment Simvastatin in people living with Parkinson's is getting underway in centres across the country -- with the hope that it could become one of a number of effective treatments available to treat Parkinson's.

12 Jan 2016

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine.

11 Jan 2016

TTUHSC researcher gets $3.82 million NIH grant to prepare Schistosomiasis Vaccine for clinical trials

Texas Tech University Health Sciences Center researcher Afzal A. Siddiqui, Ph.D., a Grover E. Murray Distinguished Professor at the TTUHSC School of Medicine, received a $3.82 million grant from the National Institutes of Health (NIH).

7 Jan 2016

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

The Sohn Conference Foundation today announced a $50,000 grant to support funding of a Phase 2 cutting-edge pediatric clinical trial from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) now extending to New York City.

6 Jan 2016

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Children and young adults with severe forms of epilepsy that does not respond to standard antiepileptic drugs have fewer seizures when treated with purified cannabinoid, according to a multi-center study led by researchers from UCSF Benioff Children's Hospital San Francisco.

6 Jan 2016

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.

6 Jan 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA.

5 Jan 2016

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

Sound Pharmaceuticals is pleased to announce that it began enrolling a clinical trial to test SPI-1005 in the treatment of Meniere's Disease (MD). MD or idiopathic endolymphatic hydrops is an inner ear disease that involves episodic vertigo, sensorineural hearing loss, and tinnitus.

5 Jan 2016

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers.

5 Jan 2016

New phase III trial takes intravaginal DHEA a step closer to approval

A new phase III trial with positive results is taking intravaginal DHEA a step closer to governmental approval. The formulation could provide women who cannot or do not wish to use intravaginal estrogen with an effective vaginal alternative for easing vaginal symptoms and pain with sex after menopause.

5 Jan 2016

Hydroxyurea could be a viable option for children with sickle cell disease

A national sickle cell disease study involving Medical University of South Carolina researchers found that for some children with sickle cell disease, the drug hydroxyurea is as effective as blood transfusions to reduce blood flow speeds in the brain. Increased blood flows are a major risk factor for stroke in these children.

5 Jan 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer announced today that new research findings on Xofigo (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco.

4 Jan 2016

NCCLC patients with KRAS-related gene mutations may benefit from triple therapy

Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment. (New therapies exist for NCCLC patients whose cancers harbor mutations in the ALK or EGFR genes, for example.)

4 Jan 2016

Drug Trial News

Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

CTCA at Western announces launch of Phase II NivoPlus clinical trial

TTUHSC researcher gets $3.82 million NIH grant to prepare Schistosomiasis Vaccine for clinical trials

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

New phase III trial takes intravaginal DHEA a step closer to approval

Hydroxyurea could be a viable option for children with sickle cell disease

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

NCCLC patients with KRAS-related gene mutations may benefit from triple therapy

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News